ANAB - AnaptysBio Inc logo

AnaptysBio Inc

ANAB

AnaptysBio, Inc. develops immunology therapeutics for autoimmune and inflammatory diseases. Its pipeline includes candidates like Rosnilimab for rheumatoid arthritis and Imsidolimab for psoriasis, targeted toward both U.S. patients and clinical trials.

โš•๏ธ Healthcare NASDAQ Listed 2017 $ USD
$1,000 invested 5 years ago โ†’$2,118today

Score Overview

1 Year
Score
Net Growth16x
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth1.28%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score7.0
Net Growth438.64%
Net Trend60%
Net Income Consistencyโ€”
Rev Growth276.12%
Rev Trend80%
Revenue Consistencyโ€”
All Time
Score
Net Growth8x
Net Trend44%
Net Income Consistency
Rev Growth23x
Rev Trend67%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where AnaptysBio Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. ANAB does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-11-13
$ 46.25โ€”
1 Year2025-11-13
$ 22.17108.58%
5 Years2021-11-12
$ 21.83111.83%
All Time2017-01-26
$ 11.33308.09%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 237M$ 195M$ 164M
2025$ 234M-$ 13M$ 311M
2024$ 91M-$ 145M$ 385M
2023$ 17M-$ 163M$ 390M
2022$ 10M-$ 128M$ 441M
2021$ 63M-$ 57M$ 548M
2020$ 75M-$ 19M$ 393M
2019$ 8M-$ 97M$ 374M
2018$ 5M-$ 61M$ 427M
IPO2017$ 10M-$ 30M$ 248M
ANAB - AnaptysBio Inc logo

AnaptysBio Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 75M to $ 234M and net income went from -$ 19M to -$ 13M. Revenue increased in 4 of those 5 years; net income in 3.

Across AnaptysBio Inc's full reported history, from 2017 to 2025, revenue grew from $ 10M to $ 234M and net income went from -$ 30M to -$ 13M. Revenue increased in 67% of the years measured; net income in 44%.

AnaptysBio Inc currently holds a 5-year HDB Score of 7.0 out of 10. How the HDB Score is calculated.

Membership

Explore ANAB with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,195 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$149 / year

or $19/month

Continue with Membership

30-day money-back guarantee.

Explore other companies